Alzheimer's disease (AD) drug developments and clinical trials (CT) remain vulnerable to problems that undermine research validity. Investigations of CT methods reveal how numerous factors decrease ac READ MORE http://www.ncbi.nlm.nih.gov/pubmed/18953116